These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12230441)

  • 21. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction.
    Liao AW; Heath V; Kametas N; Spencer K; Nicolaides KH
    Hum Reprod; 2001 Jul; 16(7):1501-4. PubMed ID: 11425838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary beta-core hCG: screening for aneuploidies in early pregnancy (11-14 weeks' gestation).
    Macintosh MC; Nicolaides KH; Noble P; Chard T; Gunn L; Iles R
    Prenat Diagn; 1997 May; 17(5):401-5. PubMed ID: 9178313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
    Tul N; Spencer K; Noble P; Chan C; Nicolaides K
    Prenat Diagn; 1999 Nov; 19(11):1035-42. PubMed ID: 10589055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation.
    Pandya PP; Snijders RJ; Johnson SP; De Lourdes Brizot M; Nicolaides KH
    Br J Obstet Gynaecol; 1995 Dec; 102(12):957-62. PubMed ID: 8652486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maternal serum screening for trisomy 18 in the first trimester of pregnancy.
    Biagiotti R; Cariati E; Brizzi L; Cappelli G; D'Agata A
    Prenat Diagn; 1998 Sep; 18(9):907-13. PubMed ID: 9793972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation.
    Sebire NJ; Snijders RJ; Hughes K; Sepulveda W; Nicolaides KH
    Br J Obstet Gynaecol; 1996 Oct; 103(10):999-1003. PubMed ID: 8863698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased nuchal translucency in trisomy 13 fetuses at 10-14 weeks of gestation.
    Snijders RJ; Sebire NJ; Nayar R; Souka A; Nicolaides KH
    Am J Med Genet; 1999 Sep; 86(3):205-7. PubMed ID: 10482866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for Down syndrome during first trimester: a prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A.
    Forest JC; Massé J; Moutquin JM
    Clin Biochem; 1997 Jun; 30(4):333-8. PubMed ID: 9209792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maternal serum hCG and SP1 in pregnancies with fetal aneuploidy.
    Bartels I; Thiele M; Bogart MH
    Am J Med Genet; 1990 Oct; 37(2):261-4. PubMed ID: 2147362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal serum inhibin-A and free beta-hCG concentrations in trisomy 21 pregnancies at 10 to 14 weeks of gestation.
    Noble PL; Wallace EM; Snijders RJ; Groome NP; Nicolaides KH
    Br J Obstet Gynaecol; 1997 Mar; 104(3):367-71. PubMed ID: 9091018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trisomy 21 and cystic hygromas in early gestational age fetuses.
    Welborn JL; Timm NS
    Am J Perinatol; 1994 Jan; 11(1):19-20. PubMed ID: 8155202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fetal heart rate in trisomy 21 and other chromosomal abnormalities at 10-14 weeks of gestation.
    Hyett JA; Noble PL; Snijders RJ; Montenegro N; Nicolaides KH
    Ultrasound Obstet Gynecol; 1996 Apr; 7(4):239-44. PubMed ID: 8726874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down syndrome prevention program in a population with an older maternal age.
    Shohat M; Legum C; Romem Y; Borochowitz Z; Bach G; Goldman B
    Obstet Gynecol; 1995 Mar; 85(3):368-73. PubMed ID: 7862374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maternal serum S100 protein in normal and Down syndrome pregnancies.
    Abraha HD; Noble PL; Nicolaides KH; Sherwood RA
    Prenat Diagn; 1999 Apr; 19(4):334-6. PubMed ID: 10327138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Importance of AFPplus-screening in daily practice. Evaluation of 2641 analyses].
    Longoni S; Ackermann M; Viollier EH
    Praxis (Bern 1994); 1997 Apr; 86(18):741-7. PubMed ID: 9244963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined use of nuchal translucency, gestational age and maternal age for evaluation of the risk of trisomy 21].
    Faraut T; Cans C; Althuser M; Jouk PS
    J Gynecol Obstet Biol Reprod (Paris); 1999 Sep; 28(5):439-45. PubMed ID: 10566163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Criteria for fetal nuchal thickness cut-off: a re-evaluation.
    Borrell A; Costa D; Martinez JM; Delgado RD; Farguell T; Fortuny A
    Prenat Diagn; 1997 Jan; 17(1):23-9. PubMed ID: 9021825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in prenatal diagnosis of Down syndrome and other autosomal trisomies in Scotland 1990 to 1994, with associated cytogenetic and epidemiological findings.
    Carothers AD; Boyd E; Lowther G; Ellis PM; Couzin DA; Faed MJ; Robb A
    Genet Epidemiol; 1999; 16(2):179-90. PubMed ID: 10030400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histomorphological features of chorionic villi at 10-14 weeks of gestation in trisomic and chromosomally normal pregnancies.
    Roberts L; Sebire NJ; Fowler D; Nicolaides KH
    Placenta; 2000 Sep; 21(7):678-83. PubMed ID: 10985971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Trisomy 21: contribution of free beta HCG for the screening of pregnancies at risk].
    Dedeystère O
    Pathol Biol (Paris); 1993 Sep; 41(7):573-4. PubMed ID: 7504806
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.